Does access to clinical study reports from the European Medicines Agency reduce reporting biases? A systematic review and meta-analysis of randomized controlled trials on the effect of erythropoiesis-stimulating agents in cancer patients

PLoS ONE

Volumn 12, Issue 12, 2017, Pages

  Rohner, Eliane ^a   Grabik, Michael ^a   Tonia, Thomy ^a   Juni, Peter ^b   Pétavy, Frank ^c   Pignatti, Francesco ^c   Bohlius, Julia ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c EUROPEAN MEDICINES AGENCY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT;

ACCESS TO INFORMATION; ADVERSE EVENT; ANEMIA; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL OUTCOME; EUROPEAN MEDICINES AGENCY; FUNCTIONAL ASSESSMENT OF CANCER THERAPY ANEMIA SCALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY ANEMIA TOTAL SCALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY FATIGUE SCALE; HUMAN; INFORMATION PROCESSING; META ANALYSIS; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; COMPLICATION; NEOPLASM; PUBLISHING;

ANEMIA; HEMATINICS; HUMANS; NEOPLASMS; PUBLICATION BIAS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85038442591     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0189309     Document Type: Article

References (41)

1. Krzyzanowska MK, Pintilie M, Tannock IF. Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA. 2003; 290: 495-501. https://doi.org/10.1001/jama.290.4.495 PMID: 12876092
2. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008; 358: 252-60. https://doi.org/10.1056/NEJMsa065779 PMID: 18199864
3. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ. 2010; 340: c365. https://doi.org/10.1136/bmj.c365 PMID: 20156912
4. Humaidan P, Polyzos NP. (Meta)analyze this: Systematic reviews might lose credibility. Nat Med. 2012; 18:1321. https://doi.org/10.1038/nm0912-1321 PMID: 22961151
5. Golder S, Loke YK, Wright K, Norman G. Reporting of Adverse Events in Published and Unpublished Studies of Health Care Interventions: A Systematic Review. Ioannidis JP, editor. PLOS Med. 2016; 13: e1002127. https://doi.org/10.1371/journal.pmed.1002127 PMID: 27649528
6. Simes RJ. Publication bias: the case for an international registry of clinical trials. J Clin Oncol. 1986; 4: 1529-1541. https://doi.org/10.1200/JCO.1986.4.10.1529 PMID: 3760920
7. Wayant C, Scheckel C, Hicks C, Nissen T, Leduc L, Som M, et al. Evidence of selective reporting bias in hematology journals: A systematic review. PLoS One. 2017; 12(6):e0178379. https://doi.org/10.1371/journal.pone.0178379 PMID: 28570573
8. Tonia T, Schwarzer G, Bohlius J. Cancer, meta-analysis and reporting biases: the case of erythropoiesis-stimulating agents. Swiss Med Wkly. 2013; 143: w13776. https://doi.org/10.4414/smw.2013.13776 PMID: 23740272
9. Vera-Badillo FE, Napoleone M, Krzyzanowska MK, Alibhai SMH, Chan A-W, Ocana A, et al. Bias in reporting of randomised clinical trials in oncology. Eur J Cancer. 2016; 61: 29-35. https://doi.org/10.1016/j.ejca.2016.03.066 PMID: 27151552
10. Wieseler B, Wolfram N, McGauran N, Kerekes MF, Vervölgyi V, Kohlepp P, et al. Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data. Ghersi D, editor. PLoS Med. 2013; 10: e1001526. https://doi.org/10.1371/journal.pmed.1001526 PMID: 24115912
11. Maund E, Tendal B, Hrobjartsson A, Jorgensen KJ, Lundh A, Schroll J, et al. Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications. BMJ. 2014; 348: g3510-g3510. https://doi.org/10.1136/bmj.g3510 PMID: 24899650
12. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet. 2004; 363:1341-5. https://doi.org/10.1016/S0140-6736(04)16043-1 PMID: 15110490
13. Eyding D, Lelgemann M, Grouven U, Harter M, Kromp M, Kaiser T, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ. 2010; 341: c4737-c4737. https://doi.org/10.1136/bmj.c4737 PMID: 20940209
14. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine-selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ. 2003; 326:1171-3. https://doi.org/10.1136/bmj.326.7400.1171 PMID: 12775615
15. Wieseler B, McGauran N, Kaiser T. We need access to data on all clinical trials, not just some. BMJ. 2012; 345: e8001. https://doi.org/10.1136/bmj.e8001 PMID: 23183067
16. Bonini S, Eichler H-G, Wathion N, Rasi G. Transparency and the European Medicines Agency-sharing of clinical trial data. N Engl J Med. 2014; 371: 2452-5. https://doi.org/10.1056/NEJMp1409464 PMID: 25539105
17. Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012; 12: CD003407. https://doi.org/10.1002/14651858.CD003407.pub5 PMID: 23235597
18. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennet C, et al. Erythropoietin for patients with malignant disease. Cochrane Database Syst Rev. 2004; 3: CD003407. https://doi.org/10.1002/14651858.CD003407.pub2 PMID: 15266483
19. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. Erythropoietin or Darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2006; 3: CD003407. https://doi.org/10.1002/14651858.CD003407.pub4 PMID: 16856007
20. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Erythropoietin or Darbepoetin for patients with cancer-meta-analysis based on individual patient data. Cochrane Database Sys Rev. 2009; 3: CD007303. https://doi.org/10.1002/14651858.CD007303.pub2 PMID: 19588423
21. Higgins JPT, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.handbook-5-1.cochrane.org.
22. Cella D, Eton DT, Lai J-S, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage. 2002; 24: 547-61. PMID: 12551804
23. Bohlius J, Tonia T, Nüesch E, Juni P, Fey MF, Egger M, et al. Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data. Br J Cancer. 2014; 111: 33-45. https://doi.org/10.1038/bjc.2014.171 PMID: 24743705
24. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet (London, England). 2009; 373:1532-42. https://doi.org/10.1016/S0140-6736(09)60502-X
25. MF4362. Open-label, randomized phase III study to investigate the effect of epoetin beta on blood transfusion need in children with various malignant solid tumours treated with chemotherapy. 2006.
26. XM01-23. Efficacy and safety of XM01 compared to placebo in anaemic patients with low grade non-Hodgkin's lymphoma, chronic lymphocytic leukaemia or multiple myeloma receiving anticancer therapy. 2008.
27. Untch M, von Minckwitz G, Konecny GE, Conrad U, Fett W, Kurzeder C, et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer-outcome on prognosis. Ann Oncol. 2011; 22:1999-2006. https://doi.org/10.1093/annonc/mdq713 PMID: 21382868
28. Strauss H-G, Haensgen G, Dunst J, Hayward CRW, Burger H-U, Scherhag A, et al. Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer. Int J Gynecol Cancer. 2008; 18: 515-24. https://doi.org/10.1111/j.1525-1438.2007.01032.x PMID: 17645506
29. Tjulandin SA, Bias P, Elsässer R, Gertz B, Kohler E, Buchner A. Epoetin Theta in Anaemic Cancer Patients Receiving Platinum-Based Chemotherapy: A Randomised Controlled Trial. Arch Drug Inf. 2010; 3: 45-53. https://doi.org/10.1111/j.1753-5174.2010.00030.x PMID: 21331363
30. Tjulandin SA, Bias P, Elsässer R, Gertz B, Kohler E, Buchner A. Epoetin Theta with a New Dosing Schedule in Anaemic Cancer Patients Receiving Nonplatinum-Based Chemotherapy: A Randomised Controlled Trial. Arch Drug Inf. 2011; 4: 33-41. https://doi.org/10.1111/j.1753-5174.2011.00035.x PMID: 22022341
31. Osterborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, et al. Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human Erythropoietin, Epoetin Beta, in Hematologic Malignancies. J Clin Oncol. 2002; 20: 2486-2494. https://doi.org/10.1200/JCO.2002.08.131 PMID: 12011126
32. Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood. 1995; 86: 4446-53. PMID: 8541533
33. Henke M, Laszig R, Rübe C, Schäfer U, Haase K-D, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003; 362:1255-1260. https://doi.org/10.1016/S0140-6736(03)14567-9 PMID: 14575968
34. Nitz U, Gluz O, Zuna I, Oberhoff C, Reimer T, Schumacher C, et al. Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer†. Ann Oncol. 2014; 25: 75-80. https://doi.org/10.1093/annonc/mdt505 PMID: 24356620
35. Smith RE, Aapro MS, Ludwig H, Pintér T, Smakal M, Ciuleanu TE, et al. Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. J Clin Oncol. 2008; 26:1040-1050. https://doi.org/10.1200/JCO.2007.14.2885 PMID: 18227526
36. Oberhoff C, Neri B, Amadori D, Petry KU, Gamucci T, Rebmann U, et al. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol Off J Eur Soc Med Oncol. 1998; 9: 255-60.
37. Tonelli M, Hemmelgarn B, Reiman T, Manns B, Reaume MN, Lloyd A, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ. 2009; 180: E62-71. https://doi.org/10.1503/cmaj.090470 PMID: 19407261
38. Minton O, Richardson A, Sharpe M, Hotopf M, Stone P. Drug therapy for the management of cancer-related fatigue. Cochrane Database Sys Rev. 2010; 7: CD006704. https://doi.org/10.1002/14651858.CD006704.pub3 PMID: 20614448
39. Grant MD, Piper M, Bohlius J, Tonia T, Robert N, Vats V, et al. Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment. Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment: Comparative Effectiveness Update. Agency for Healthcare Research and Quality (US); 2013.
40. Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database Syst Rev. 2014; 4: CD008965. https://doi.org/10.1002/14651858.CD008965.pub4 PMID: 24718923
41. Davis AL, Miller JD. The European Medicines Agency and Publication of Clinical Study Reports: A Challenge for the US FDA. JAMA. 2017; 317: 905-906. https://doi.org/10.1001/jama.2017.0918 PMID: 28241281